» Articles » PMID: 38128546

At Home Adaptive Dual Target Deep Brain Stimulation in Parkinson's Disease with Proportional Control

Overview
Journal Brain
Specialty Neurology
Date 2023 Dec 21
PMID 38128546
Authors
Affiliations
Soon will be listed here.
Abstract

Continuous deep brain stimulation (cDBS) of the subthalamic nucleus (STN) or globus pallidus is an effective treatment for the motor symptoms of Parkinson's disease. The relative benefit of one region over the other is of great interest but cannot usually be compared in the same patient. Simultaneous DBS of both regions may synergistically increase the therapeutic benefit. Continuous DBS is limited by a lack of responsiveness to dynamic, fluctuating symptoms intrinsic to the disease. Adaptive DBS (aDBS) adjusts stimulation in response to biomarkers to improve efficacy, side effects, and efficiency. We combined bilateral DBS of both STN and globus pallidus (dual target DBS) in a prospective within-participant, clinical trial in six patients with Parkinson's disease (n = 6, 55-65 years, n = 2 females). Dual target cDBS was tested for Parkinson's disease symptom control annually over 2 years, measured by motor rating scales, on time without dyskinesia, and medication reduction. Random amplitude experiments probed system dynamics to estimate parameters for aDBS. We then implemented proportional-plus-integral aDBS using a novel distributed (off-implant) architecture. In the home setting, we collected tremor and dyskinesia scores as well as individualized β and DBS amplitudes. Dual target cDBS reduced motor symptoms as measured by Unified Parkinson's Disease Rating Scale (UPDRS) to a greater degree than either region alone (P < 0.05, linear mixed model) in the cohort. The amplitude of β-oscillations in the STN correlated to the speed of hand grasp movements for five of six participants (P < 0.05, Pearson correlation). Random amplitude experiments provided insight into temporal windowing to avoid stimulation artefacts and demonstrated a correlation between STN β amplitude and DBS amplitude. Proportional plus integral control of aDBS reduced average power, while preserving UPDRS III scores in the clinic (P = 0.28, Wilcoxon signed rank), and tremor and dyskinesia scores during blinded testing at home (n = 3, P > 0.05, Wilcoxon ranked sum). In the home setting, DBS power reductions were slight but significant. Dual target cDBS may offer an improvement in treatment of motor symptoms of Parkinson's disease over DBS of either the STN or globus pallidus alone. When combined with proportional plus integral aDBS, stimulation power may be reduced, while preserving the increased benefit of dual target DBS.

Citing Articles

Proceedings of the 12th annual deep brain stimulation think tank: cutting edge technology meets novel applications.

Martinez-Nunez A, Rozell C, Little S, Tan H, Schmidt S, Grill W Front Hum Neurosci. 2025; 19:1544994.

PMID: 40070487 PMC: 11893992. DOI: 10.3389/fnhum.2025.1544994.


Field-Programmable Gate Array-Based Ultra-Low Power Discrete Fourier Transforms for Closed-Loop Neural Sensing.

Yang R, Orser H, Ludwig K, Coventry B bioRxiv. 2025; .

PMID: 39990505 PMC: 11844513. DOI: 10.1101/2025.02.13.637868.


Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report.

Cernera S, Oehrn C, Hammer L, Shcherbakova M, Yao J, Hahn A Mov Disord. 2024; 40(2):345-350.

PMID: 39629629 PMC: 11835528. DOI: 10.1002/mds.30076.


Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator.

Saengphatrachai W, Jimenez-Shahed J Neurodegener Dis Manag. 2024; 14(5):131-147.

PMID: 39344591 PMC: 11524207. DOI: 10.1080/17582024.2024.2404386.


Deep Brain Stimulation (DBS) in Treatment-Resistant Depression (TRD): Hope and Concern.

Asir B, Boscutti A, Fenoy A, Quevedo J Adv Exp Med Biol. 2024; 1456:161-186.

PMID: 39261429 DOI: 10.1007/978-981-97-4402-2_9.


References
1.
Swann N, de Hemptinne C, Miocinovic S, Qasim S, Wang S, Ziman N . Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease. J Neurosci. 2016; 36(24):6445-58. PMC: 5015781. DOI: 10.1523/JNEUROSCI.1128-16.2016. View

2.
Odekerken V, Boel J, Schmand B, de Haan R, Figee M, van den Munckhof P . GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up. Neurology. 2016; 86(8):755-61. DOI: 10.1212/WNL.0000000000002401. View

3.
Opri E, Cernera S, Molina R, Eisinger R, Cagle J, Almeida L . Chronic embedded cortico-thalamic closed-loop deep brain stimulation for the treatment of essential tremor. Sci Transl Med. 2020; 12(572). PMC: 8182660. DOI: 10.1126/scitranslmed.aay7680. View

4.
Chen W, Kirkby L, Kotzev M, Song P, Gilron R, Pepin B . The Role of Large-Scale Data Infrastructure in Developing Next-Generation Deep Brain Stimulation Therapies. Front Hum Neurosci. 2021; 15:717401. PMC: 8450349. DOI: 10.3389/fnhum.2021.717401. View

5.
Azghadi A, Rajagopal M, Atkinson K, Holloway K . Utility of GPI+VIM dual-lead deep brain stimulation for Parkinson's disease patients with significant residual tremor on medication. J Neurosurg. 2021; 136(5):1364-1370. DOI: 10.3171/2021.4.JNS21502. View